UNSPSC 51401533: Lorazepam

This classification denotes a benzodiazepine and antiemetic agent with the molecular formula C15H10Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O26FZP769L, chemically known as 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2h-1,4-benzodiazepin-2-one but generally known as lorazepam, which bears US NIH Compound Identifier 3958. European Medicines Agency schedules Lorazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08582MIG.

UNSPSC 51401533 Lorazepam is a Commodity code that captures pharmaceutical procurement by state and local government bodies, though recent opportunities under this code show no direct lorazepam solicitations but rather broader pharmaceutical and prescription-management initiatives. State and local governments buying under this code range from individual county health departments to multistate cooperative purchasing alliances and state health agencies. The work being solicited spans manufacturer-direct pharmaceutical supply agreements, generic and over-the-counter product procurement through authorized wholesalers, and specialized drug management systems including naloxone distribution and drug deactivation capabilities. Issuing bodies include county-level health and public safety departments, state health and human services commissions, and cooperative purchasing organizations serving multiple states and subdivisions.

Recent activity shows Seminole County, Florida posting an IFB (IFB60459723LAS) due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posting an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities including Oregon, with awards effective July 1, 2026; and the Texas Health and Human Services Commission posting an RFI (HHS0017013) due April 3, 2026, exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Geographic activity spans Florida, Minnesota and Oregon under MMCAP, and Texas. Recent solicitations emphasize compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, Federal Water Pollution Control Act, and the Clean Air Act, with vendors required to maintain specific insurance coverage, E-Verify compliance, and drug-free workplace certification.